Mostrar el registro sencillo del ítem

dc.rights.licenseopenen_US
hal.structure.identifierMicrobiologie Fondamentale et Pathogénicité [MFP]
dc.contributor.authorPREVEL, Renaud
hal.structure.identifierCHU de Bordeaux Pellegrin [Bordeaux]
dc.contributor.authorBOYER, Alexandre
hal.structure.identifierMicrobiologie Fondamentale et Pathogénicité [MFP]
dc.contributor.authorM'ZALI, Fatima
hal.structure.identifierUniversité de Bordeaux [UB]
dc.contributor.authorCOCKENPOT, Thibaut
hal.structure.identifierCHU Bordeaux
dc.contributor.authorLASHERAS, Agnes
hal.structure.identifierMicrobiologie Fondamentale et Pathogénicité [MFP]
dc.contributor.authorDUBOIS, Veronique
hal.structure.identifierCHU de Bordeaux Pellegrin [Bordeaux]
dc.contributor.authorGRUSON, Didier
dc.date.accessioned2023-12-04T12:28:20Z
dc.date.available2023-12-04T12:28:20Z
dc.date.issued2019-01-01
dc.identifier.issn2047-2994en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/186333
dc.description.abstractEnExtended-spectrum beta-lactamases-producing (ESBL-E) are disseminating worldwide especially in Intensive Care Units (ICUs) and are responsible for increased health costs and mortality. The aims of this work were to study ESBL-E dissemination in ICU and to assess the impact of ESBL-E fecal carriage on subsequent infections during a non-outbreak situation. We therefore screened every patient at admission then once a week in a medical ICU between January and June 2015. Each ESBL-E isolate was characterized by ESBL genes PCR amplification and the clonal dissemination was assessed by Pulsed-Field Gel Electrophoresis (PFGE). Among the 608 screened patients, 55 (9%) were colonized by ESBL-E. Forty-four isolates were available for further analysis. Most of them (43/44, 98%) contained a ESBL gene from the CTX-M group. Only one case of ESBL-E cross-transmission occurred, even for acquired ESBL-E colonization. Subsequent infection by ESBL-E occurred in 6/55 (11%) patients and infecting ESBL-E strains were the colonizing ones. ESBL-E faecal carriage had a negative predictive value of 100% and a positive predictive value of 40% to predict ESBL-E ventilator associated-pneumonia (VAP). Alternatives to carbapenems consisting in piperacillin-tazobactam, ceftolozane-tazobactam and ceftazidime-avibactam were all active on this panel of ESBL-E. ESBL-E expansion and acquisition in ICU in a non-outbreak situation are not any more fully explained by cross-transmission. Mechanisms underlying ESBL-E dissemination in ICU are still to investigate. Interestingly, as far as we know, our study demonstrates for the first time by PFGE that the colonizing strain is indeed the infecting one in case of subsequent ESBL-E infection. Nevertheless, subsequent ESBL-E infection remains a rare event conferring poor positive predictive value for ESBL-E colonization to predict ESBL-E VAP. Relevance of systematic ESBL-E faecal screening at ICU admission and during ICU stay needs further investigation.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enAdult
dc.subject.enAged
dc.subject.enAged
dc.subject.en80 and over
dc.subject.enBacterial Proteins
dc.subject.enCarbapenems
dc.subject.enCarrier State
dc.subject.enCross Infection
dc.subject.enElectrophoresis
dc.subject.enGel
dc.subject.enPulsed-Field
dc.subject.enEnterobacteriaceae
dc.subject.enEnterobacteriaceae Infections
dc.subject.enFeces
dc.subject.enFemale
dc.subject.enHumans
dc.subject.enIntensive Care Units
dc.subject.enMale
dc.subject.enMicrobial Sensitivity Tests
dc.subject.enMiddle Aged
dc.subject.enbeta-Lactamases
dc.title.enExtended spectrum beta-lactamase producing faecal carriage in a medical intensive care unit: low rates of cross-transmission and infection.
dc.title.alternativeAntimicrob Resist Infect Controlen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1186/s13756-019-0572-9en_US
dc.subject.halSciences du Vivant [q-bio]/Microbiologie et Parasitologieen_US
dc.identifier.pubmed31333839en_US
bordeaux.journalAntimicrobial Resistance and Infection Controlen_US
bordeaux.page112en_US
bordeaux.volume8en_US
bordeaux.hal.laboratoriesMFP (Laboratoire Microbiologie Fondamentale et Pathogénicité) - UMR 5234en_US
bordeaux.institutionCNRSen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcepubmed
hal.identifierhal-04320948
hal.version1
hal.date.transferred2023-12-04T12:28:22Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
workflow.import.sourcepubmed
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Antimicrobial%20Resistance%20and%20Infection%20Control&rft.date=2019-01-01&rft.volume=8&rft.spage=112&rft.epage=112&rft.eissn=2047-2994&rft.issn=2047-2994&rft.au=PREVEL,%20Renaud&BOYER,%20Alexandre&M'ZALI,%20Fatima&COCKENPOT,%20Thibaut&LASHERAS,%20Agnes&rft.genre=article


Archivos en el ítem

Thumbnail
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem